Rubicon Research enters high-growth CNS segment with 85% stake acquisition in Arinna Lifesciences
News by Aliceblue News Desk
16 Apr 2026
Introduction
Leading pharmaceutical company acquires 85 percent stake in Arinna Lifesciences on 15 April 2026, entering India CNS formulations market with expanded portfolio.
Also Read: Time Technoplast signs MoU to acquire 76% stake in Systoverse Private Limited
Share price movement of Rubicon Research
On April 16, 2026, Rubicon Research Ltd opened at ₹860.05, up 4.30% from its previous close of ₹824.55. The stock reached a high of ₹900.10 (9.17%) and a low of ₹829.00. By 14:32, it traded at ₹871.85, a 5.74% increase, with a market cap of ₹14,393.56 crore.
Rubicon Acquires Majority Stake in Arinna
Rubicon Research acquired 85% equity in Arinna Lifesciences Limited on 15 April 2026. The deal marks entry into India’s CNS formulations market.
Arinna has over 60 brands in chronic therapies focused on central nervous system treatments. It serves 4,000 prescribers through distributors, stockists, and retail pharmacy networks.
The acquisition supports Rubicon’s strategy in CNS therapies and chronic products. It also expands access to Arinna’s distribution network and specialty drug pipeline in India.
Stock performance of Rubicon Research for period of 1 week, 1 month, and 6 months
Rubicon Research Ltd delivered a 1-week return of -4.08%, a 1-month return of 9.19%, and a 6-month return of 32.7%.
Shareholding pattern of Rubicon Research
| Particulars | Dec 2025 | Oct 2025 |
| Promoter | 60.00% | 60.00% |
| FII | 8.00% | 9.40% |
| DII | 9.50% | 10.50% |
| Public | 22.60% | 20.10% |
About Rubicon Research
Rubicon Research Limited (NSE: RUBICON) is a pharmaceutical company developing and commercialising differentiated drugs with R&D, CDMO capabilities, and global regulated manufacturing facilities.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Rubicon Research Ltd share price rising today?
A: Rubicon Research Ltd rose after acquiring 85% stake in Arinna Lifesciences on 15 April 2026, expanding CNS market presence.
Q: What is Rubicon Research Ltd’s main business focus?
A: Rubicon Research Ltd focuses on pharmaceutical R&D, CDMO services, and differentiated drug development across multiple therapeutic areas globally.
Q: What are the 52-week high and low of Rubicon Research Ltd stock?
A: Rubicon Research Ltd 52-week high is ₹900.10 and low is ₹571.00, reflecting trading range over the period.
News Author
Aliceblue News Desk
